- Home
- EDN vs IMTX Comparison
EDN vs IMTX Comparison
Compare EDN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$10.34
Company Overview
Basic Information| Metric | EDN | IMTX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | Argentina | Germany |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDN | IMTX |
|---|---|---|
| Price | $33.01 | $10.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.25 |
| AVG Volume (30 Days) | 142.1K | ★ 657.4K |
| Earning Date | 08-11-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | $99,445,031.00 |
| Revenue This Year | $32.93 | N/A |
| Revenue Next Year | $24.64 | $24.39 |
| P/E Ratio | $20.87 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $14.38 | $3.30 |
| 52 Week High | $51.69 | $12.41 |
Technical Indicators
Market Signals| Indicator | EDN | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 50.83 |
| Support Level | $33.65 | $9.76 |
| Resistance Level | $36.70 | $12.41 |
| Average True Range (ATR) | 2.31 | 0.86 |
| MACD | -0.38 | -0.03 |
| Stochastic Oscillator | 43.18 | 35.78 |
Price Performance
Historical Comparison EDN
IMTX
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.